ABCB4 gene mutation-associated cirrhosis with systemic amyloidosis: A case report

Table 1 Results of the laboratory examination

Analyte	November, 2018	July, 2020	August, 2021	December, 2021	January, 2022	March, 2022	April, 2022	May, 2022	Reference range
WBC as × 109/L	1.14	14.94	10.1	9.6	13.9	9.6	7.8	8.5	3.5-9.5
Hb in g/L	83	97	96	86	97	91	88	95	115-150
PLT as × 109L	33	359	253	316	267	377	361	345	125-350
ALT in U/L	58.2	33.6	56.1	81.9	66.2	716	42.8	31.6	7-40
AST in U/L	136.4	108.6	175.8	236.5	315.2	298.3	211.9	125.8	13-35
TBIL in μmol/L	66.1	179	14.2	46.9	67.2	36.9	33.2	23.04	< 23
DBIL in μmol/L	47.8	128.6	9	31.85	39.2	26.7	18.39	13.81	≤ 8
ALB in g/L	35.3	24.6	16.9	25.86	22.71	26.39	25.33	27.58	40-55
ALP in U/L	501	1174	426	904	887	1160	875	978	35-100
GGT in U/L	268.26	1367	439.51	387.3	971.19	554	382	542.22	7-45
ChE in U/L	2796	2301	3958	4623	3112	4728	2738	3288	5000-12000
CREA in μmol/L	48	49.83	56.87	/	96.6	66	68	46.9	41-73
NT-proBNP in pg/mL	/	176	238.4	/	3020	475	/	110.9	41.4-153
cTnT in ng/mL	0.003	0.009	/	/	0.645	0.465	/	0.001	0-0.014
LDH in U/L	136	244	279	426	295	481	364	290	120-250
uPRO	/	Positive (2 +)	Positive (3 +)	Positive (3 +)	Positive (3 +)	Positive (3 +)	Positive (2 +)	Positive (1 +)	Negative (-)
uALB in mg/L	/	964	/	/	744.98	/	/	352.17	< 140
Serum κ light chain in mg/dL	/	/	/	/	1050	1710	689	649	629-1350
Serum λ light chain in mg/dL	/	/	/	/	537	916	330	249	313-723
Urinary κ light chain in mg/dL	/	/	/	/	52	72.4	/	4.08	0-1.85
Urinary λ light chain in mg/dL	/	/	/	/	37.9	62.5	/	< 5	0-5
Drug	UDCA					UDCA + Daratumumab

ALB: Albumin; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ChE: Choline; CREA: Creatinine; cTNT: Cardiac troponin T; DBIL: Direct bilirubin; GGT: Gamma-glutamyl transpeptidase; Hb: Hemoglobin; LDH: Lactate dehydrogenase; NT-proBNP: N-terminal pro-B-type natriuretic peptide; PLT: Platelet count; TBIL: Total bilirubin; uALB: Urine albumin; UDCA: Ursodeoxycholic acid; uPRO: Urine protein; WBC: White blood cell.